PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009040/ https://www.ncbi.nlm.nih.gov/pubmed/29921237 http://dx.doi.org/10.1186/s12885-018-4412-8 |
_version_ | 1783333303963615232 |
---|---|
author | Li, Yuan Du, Yang Sun, Ting Xue, Huadan Jin, Zhengyu Tian, Jie |
author_facet | Li, Yuan Du, Yang Sun, Ting Xue, Huadan Jin, Zhengyu Tian, Jie |
author_sort | Li, Yuan |
collection | PubMed |
description | BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. METHODS: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. RESULTS: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. CONCLUSION: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment. |
format | Online Article Text |
id | pubmed-6009040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60090402018-06-27 PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model Li, Yuan Du, Yang Sun, Ting Xue, Huadan Jin, Zhengyu Tian, Jie BMC Cancer Research Article BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. METHODS: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. RESULTS: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. CONCLUSION: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment. BioMed Central 2018-06-19 /pmc/articles/PMC6009040/ /pubmed/29921237 http://dx.doi.org/10.1186/s12885-018-4412-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Li, Yuan Du, Yang Sun, Ting Xue, Huadan Jin, Zhengyu Tian, Jie PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title | PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title_full | PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title_fullStr | PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title_full_unstemmed | PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title_short | PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
title_sort | pd-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009040/ https://www.ncbi.nlm.nih.gov/pubmed/29921237 http://dx.doi.org/10.1186/s12885-018-4412-8 |
work_keys_str_mv | AT liyuan pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel AT duyang pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel AT sunting pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel AT xuehuadan pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel AT jinzhengyu pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel AT tianjie pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel |